Both Adele and I can sing.

Congrats Roni! Excellent work!

First in Human GPRC5D CAR T cell trial presented by Sham Mailankody, N=17, 59% prior BCMA, CRS 93%, 7% NT, 56% Gr1 nail changes, 19% Gr1 rash, ORR 69%, short mFU 17.9 weeks @sloan_kettering MSKHemOncTrials #mmsm #ASH21 #ASH21_MSKMM

#ASH21 @sloan_kettering Ana Alarcon Tomas Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19 #CARTcells - very challenging disease to treat #lymsm 1/2

Fantastic job giulia_biancon!!! Brava!!!

CAR T-Cell Therapy ARI0002H Elicits Encouraging Responses in Relapsed/Refractory Multiple Myeloma Carlos Fernandez de Larrea Universitat de Barcelona European Hematology Association #EHA22 #mmsm onclive.com/view/car-t-cel…

Carniti studied leukopheresis products for #CARTcells & showed 4 🧬 signature that correlates with OS. #ASH22

First ph3 trial comparing ide-cel vs SoC regimens in TCE early relapsed MM. Ide-cel significantly prolonged PFS and ORR. Thanks to our patients and all the team. Krina Patel Luciano J Costa #SergioGiralt nizar jacques bahlis et al. NEJM Clínica Universidad de Navarra

Really a great EHA-EBMT CAR-T meeting in Rotterdam. Nice data and nice interaction with colleagues. #CART23 Anna Sureda Marco Ruella Emily Whitehead Foundation European Hematology Association The EBMT

🎉Finally out🎉 Stem cell boost for persistent neutropenia after CAR-T cell therapy. 👉recovery rate 84% in median of 9 days 👉shorter duration of neutropenia before boost associated with response and outcome #lymsm ashpublications.org/bloodadvances/…

Oggi è stata una giornata straordinaria in cui la SIE ha incontrato tutte le associazioni pazienti per lavorare meglio insieme .#sie #ematologia #ail #pazienti #ricerca

Great to see the escBEACOPDac data on MedRxiv. Procarbazine is genotoxic - much less so with dacarbazine and clinical outcomes similar. So until BreCADD funded, it's escBEACOPDac when intensive chemo needed in Hodgkin. medrxiv.org/content/10.110…

Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel ascopost.com/videos/2024-as… #mmsm #MultipleMyeloma #hematology #ASCO24 UAB Luciano J Costa

Lavie - epcor + Pola-R-CHP 1L DLBCL - fixed durn epco - 37 pts - ORR 100% / CRR 89% - 49% had CRS but all G1/2 Good results but a lot of initial weekly dosing. Only G1/2 CRS but this would still needs admission as fever. #EHA24 #lymsm

Donor age <30 vs ≥30 years should supersede 10/10 vs 9/10 HLA-matching in the selection of unrelated donor for HSCT with PTCy for AML. ow.ly/pqPn50SijKg #transplantation #clinicaltrialsandobservations #myeloidneoplasia

Happy to share our multicenter analysis- CAR T therapy in Richter's transformation shows a 57% response rate and 9.9 months median OS. Efficacy is lower than de novo LBCL and transformed iNHL. Toxicities are similar. #CART #CLL #Lymphoma Haematologica haematologica.org/haematologica/…

Just out Nature Medicine meta-analysis >7600 CAR T pts led by David Cordas dos Santos & Kai Rejeski - Non-relapse mortality post CAR-T = 6.8% - highest w ciltacel (15%) & brexucel (10.6%) - axicel (7%) > tisa-/lisocel (4%) for LBCL - 51% of NRM deaths from infection nature.com/articles/s4159…

#CART ID practices effort — kudos to Zainab Shahid MD, FACP, FIDSA 🇺🇸🇵🇰 for leading this and rescuing this effort from ASTCT , and to all contributors for the critical contributions Martina Pennisi Joshua Hill, MD Swetha Kambhampati Lekha Mikkilineni and others